In the case of AD, increased CSF levels of total-tau and phosphorylated-tau protein along with decreased levels of CSF Aβ1−42 create the typical AD biomarker profile found in most AD patients (Bouwman et al., 2022). The gene discussed is MAPT; the disease is Alzheimer disease.